Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction
therapy (primary induction failure [PIF]) or relapse after< 6 months (early relapse [ER]). We …

Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46%
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …

Purpose Lintuzumab (HuM195) is an unconjugated humanized murine monoclonal antibody
directed against the cell surface myelomonocytic differentiation antigen CD33. In this study …

Background The powerful 'graft versus leukemia'effect thought partly responsible for the
therapeutic effect of allogeneic hematopoietic cell transplantation in acute myeloid leukemia …

Importance The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic
leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to …

Acute myeloid leukemia (AML) is a rapidly progressive, poor-prognosis malignancy arising
from hematopoietic stem/progenitor cells. The long history of successful use of allogeneic …

Background Given the success of immunotherapeutic approaches in hematologic
malignancies, the COG designed a phase I/II study to determine whether the addition of …

Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in
combination with decitabine in elderly patients with acute myeloid leukemia (AML) not …

Abstract Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting
of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is …

Despite being considered “good‐risk” acute myelogenous leukemia (AML), long term
outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a …